(Q36097706)

English

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

phase II clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

David R Gandara

3

object named as

David R Gandara

1 reference

Europe PubMed Central

12 August 2017

PMC publication ID

Everett E Vokes

17

object named as

Everett E Vokes

1 reference

Europe PubMed Central

12 August 2017

PMC publication ID

7

object named as

Pasi A Jänne

1 reference

Europe PubMed Central

12 August 2017

PMC publication ID

Nicholas J. Vogelzang

14

object named as

Nicholas J Vogelzang

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

author name string

Hedy L Kindler

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Theodore G Karrison

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Charles Lu

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Lee M Krug

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

James P Stevenson

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

David I Quinn

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Marianna N Koczywas

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Julie R Brahmer

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kathy S Albain

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

David A Taber

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Samuel G Armato

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Helen X Chen

15

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Walter M Stadler

16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

4 June 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

20

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

2509-2515

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Update on malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Antiangiogenic therapies for mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Thalidomide in patients with malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

The role of gemcitabine in the treatment of malignant mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 October 2017

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 July 2018

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 July 2018

Issues in designing sequential stopping rules for monitoring side effects in clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

2 July 2018

Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

23 September 2018

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

23 September 2018

Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

23 September 2018

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

23 September 2018

Prognosis of Cancers Associated with Venous Thromboembolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3397785

5 December 2018

Malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22665541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trials in journal of clinical oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22665541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.41.5869

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36097706&oldid=2201351342"